Phelps, Kenneth R., M.D. Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2010
NCT01191762
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperparathyroidism (Phase 3)

Hyperparathyroidism, Secondary (Phase 3)

Kidney Diseases (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1